NEW YORK (GenomeWeb News) — EMD Biosciences will use Starpharma’s dendrimers for DNA and siRNA transfection research, EMD said today.
Under the terms of the license and supply agreement, Starpharma’s US subsidiary Dendritic Nanotechnologies will supply EMD with the Priostar technology in exchange for royalties and milestones.
DNT will retain the full rights to use Priostarall for in vivo transfection research.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

The Atlantic reports that genetic counselors are coping with an influx of patients seeking advice on their direct-to-consumer genetic test results.

A small study finds differences between three genomic prostate cancer tests, Medscape reports.

In Nature this week: shared genetic architecture for asthma and allergic diseases, and more.

A survey of Canadians finds them to be divided on genetically modified food, the Ottawa Citizen reports.

Sponsored by
Advanced Cell Diagnostics

This webinar will provide evidence for the use of RNA in situ hybridization (RNA ISH) as a replacement for immunohistochemistry (IHC) in cancer research and diagnostic applications.